Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01189383 · ClinicalTrials.gov registry record · Phase 1
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
A Phase 1 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01189383 is a Phase 1 study that has completed, run by Baylor Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT01189383, a Phase 1 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma
Interventions
- BIOLOGICAL IL15-DC Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01189383
The ClinicalTrials.gov registry entry for NCT01189383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IL15-DC Vaccine is the first listed.
NCT01189383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01189383 about?
NCT01189383 is a clinical study titled "IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma". The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma
What is the current status of trial NCT01189383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01189383?
The interventions under investigation include: IL15-DC Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01189383?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.